Amlexanox reduces new-onset atrial fibrillation risk in sepsis by downregulating S100A12: a Mendelian randomization study
This study demonstrates that sepsis may independently increase the risk of new-onset AF. We identified S100A12 as a key gene influencing the new-onset AF in sepsis through immune regulation, presenting considerable diagnostic and predictive value. Notably, amlexanox, by targeting S100A12 emerges as the most clinical relevant intervention for managing new-onset AF in sepsis patients.
Authors
- Xiaodan Wu (ORCID: https://orcid.org/0000-0003-4602-502X)
- Zhenjie Jiang
- Hang Yang (ORCID: https://orcid.org/0000-0002-5524-4227)
- Kai Zeng (ORCID: https://orcid.org/0000-0002-4343-3207)
- Feng Lin (ORCID: https://orcid.org/0000-0002-1613-3874)
Institutions
- Fujian Medical University (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2024-10-09
- DOI
- https://doi.org/10.3389/fcvm.2024.1401314
- Citations
- 5
- Primary Topic
- S100 Proteins and Annexins
- Type
- article
- Field-Weighted Citation Impact
- 1.17